Synaptogenix Inc (SNPX)

[Antti]

Even though ongoing phase 2b is naturally where most of the interest is, it would be nice to see fragile X study to start soon. There's so big unmet need there and open label nature of the study will also allow some fairly quick initial results.

In Alzheimer's disease area it's (in some ways unfortunately) inevitable that they start to get more attention especially once the enrollment is completed and the study is on its way to completion. There are such a big and growing need and basically zero alternative treatment options. So having a great chance of getting the first and hopefully also definitive proof of big real treatment effect and even possibly disease reversal NOW for a big patient population that have no hope left should result massive amount of interest.

Only thing company really should need to do is to get the ball rolling by getting some press coverage so that people become aware of what's happening.